Communicable

CMI Communications
  • 0,0 (0)
  • МЕДИЦИНА
  • ЩОМІСЯЦЯ
Communicable

Communicable takes on hot topics in infectious diseases and clinical microbiology. Hosted by the editors of CMI Communications, the open-access journal of ESCMID, the European Society of Clinical Microbiology & Infectious Diseases.

  1. Communicable E13 - The Wild West of publishing today: predatory journals and how to deal with them

    4 ЛИСТ.

    Communicable E13 - The Wild West of publishing today: predatory journals and how to deal with them

    The market of predatory publishing is as lucrative as it is unethical. Predatory journals are disguised as legitimate entities, and prey on both early-career academics and the naïve. In this episode of Communicable, hosts Angela Huttner and Marc Bonten are joined by Editors-in-chief Ursula Hofer (Lancet Infect Dis) and Leonard Leibovici (CMI) to discuss the various schemes of the ‘Wild West’ of publishing, and how to avoid them.    This episode was edited by Kathryn Hostettler and peer-reviewed by Dr. Özlem Türkmen Recen, Izmir Public Health Laboratory, Izmir, Türkiye.   Literature    Research4Life https://www.research4life.org/    Benedictus R et al. Nature 2016 https://www.nature.com/articles/538453a

    46 хв
  2. Communicable E12 - The Nightmare Series, part 3: How to deal with vancomycin-resistant enterococci

    21 ЖОВТ.

    Communicable E12 - The Nightmare Series, part 3: How to deal with vancomycin-resistant enterococci

    Enterococci are commensal microbes, part of the healthy microflora populating the human gut. But they are also opportunistic pathogens and notorious nosocomial agents with intrinsic traits that promote their pathogenesis and make them difficult to kill. In the third instalment of the Nightmare Series, hosts Angela Huttner and Thomas Tängdén are joined by enterococcal experts Kimberly Kline (University of Geneva) and Louis Rice (Brown University) to discuss what make vancomycin-resistant enterococci, or VRE, such a clinical nightmare. Enterococcus faecalis and Enterococcus faecium are the focus.   This episode was edited by Kathryn Hostettler and peer-reviewed by Dr. Nunzia Esposito of the University of Naples Federico II, Naples, Italy.   Literature    Stellfox ME et al. J Antimicrob Chemother 14 Feb 2024. doi: 10.1128/mbio.03396-23    Rogers R & Rice LB. Clin Infect Dis 15 Jan 2024. doi: 10.1093/cid/ciad613   Lebreton F et al. Cell 18 May 2017. doi: 10.1016/j.cell.2017.04.027   Donskey CJ et al. N Engl J Med 28 Dec 2000. doi: 10.1056/NEJM200012283432604

    57 хв
  3. Communicable E11 - Nightmare series, part 2: How to deal with carbapenemase producers

    7 ЖОВТ.

    Communicable E11 - Nightmare series, part 2: How to deal with carbapenemase producers

    Carbapenemase producers are a nightmare for clinicians. Not only are they resistant to carbapenems, a last resort β-lactam antibiotic, they are notorious for developing multidrug and pandrug resistances resulting in limited to no treatment options.  In this episode of Communicable, hosts Angela Huttner and Thomas Tängdén sit down with Dr. David Paterson (National University of Singapore) and Dr. Souha Kanj (American University of Beirut Medical Center, Lebanon), two ID physicians from regions where carbapenem-resistant Enterobacteriaceae or CRE, and carbapenem-resistant Acinetobacter are widespread.  The episode begins with the history and emergence of CRE and reviews current epidemiology, diagnosis (including the Ambler classification of β-lactamases) and treatment options. Lessons and insights from personal experiences are shared to reflect the current clinical challenges caused by carbapenem-resistant bacteria and the importance of infection prevention and control measures to mitigate further spread.   This episode was edited by Kathryn Hostettler and peer-reviewed by Dr. Filippo Medioli of Policlinico di Modena, Italy. For more related content on the WHO Priority Pathogens List and new antibiotics in the pipeline, check out our previous episodes, Communicable E3 and E10 (see Literature). Literature  Communicable E3 - The New WHO Priority Pathogens List: which bugs to target first? June 2024. https://communicable.transistor.fm/episodes/communicable-e3-the-new-who-priority-pathogens-list-which-bacteria-to-target-first    Communicable E10 - Pipeline update: new antibiotics & other antimicrobials that you might actually use. Sep 2024. https://communicable.transistor.fm/episodes/communicable-e10-pipeline-update-new-antibiotics-other-antimicrobials-that-you-might-actually-use    Wagenlehner FM, et al. Cefepime-Taniborbactam in Complicated Urinary Tract Infection. N Engl J Med 2024 Feb. doi: 10.1056/NEJMoa2304748   Cohn J, et al. Accelerating antibiotic access and stewardship: a new model to safeguard public health. Lancet Infect Dis 2024 Sep. doi:  10.1016/S1473-3099(24)00070-7   Timsit JF, et al. When should I start broad-spectrum antibiotics? Intensive Care Med 2024 Sep. doi: 10.1007/s00134-024-07654-7    Paterson DL. Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials. Expert Opin Investig Drugs 2024 Apr. doi: 10.1080/13543784.2024.2326028

    1 год
  4. Communicable E10 - Pipeline update: new antibiotics & other antimicrobials that you might actually use

    23 ВЕР.

    Communicable E10 - Pipeline update: new antibiotics & other antimicrobials that you might actually use

    On the verge of a post-antibiotic reality, there is an urgent clinical need for new antibiotics. Luckily, new candidates are in the pipeline and older agents are getting a second breath of life through combination therapy.    In this episode of Communicable, host Erin McCreary invites Dr. Markus Zeitlinger of the University of Vienna (Austria) and scientific expert for the European Medicines Agency (EMA) and Dr. Michael Dudley, president and CEO of Qpex Biopharma, to discuss antimicrobials in the clinical development pipeline.  Together they unpack how the WHO curate the priority list of pathogens and how companies adapt such lists into their antimicrobial development business plans. They also discuss the unique challenges and complexities of developing antibiotics, from return on investments and defining the ‘novelty’ of an agent to the conundrum of balancing post-market approval and antimicrobial stewardship. Beta-lactamase inhibitors and oral carbapenems in the pipeline targeting ‘the big three’ (Enterobacterales, Pseudomonas and Acinetobacter) are the primary focus.   This episode was edited by Kathryn Hostettler and peer-reviewed by Dr. Benjamin Berinson of the Medical Centre Hamburg-Eppendorf (UKE), Germany. For more information on the WHO Priority Pathogens List and its 2024 update, check out our previous episode, Communicable E3 (see Literature).    Literature    Communicable E3 - The New WHO Priority Pathogens List: which bugs to target first? 17 June 2024. https://communicable.transistor.fm/episodes/communicable-e3-the-new-who-priority-pathogens-list-which-bacteria-to-target-first    WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization; 17 May 2024. https://www.who.int/publications/i/item/9789240093461    C. Le Terrier et al, NDM-9 resistance to taniborbactam. Lancet Infect Dis 23, 401-402 (2023). doi 10.1016/S1473-3099(23)00069-5        P. B. Eckburg et al, Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection. N Engl J Med 386, 1327-1338 (2022). doi: 10.1056/NEJMoa2105462    A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (PIVOT-PO). https://clinicaltrials.gov/study/NCT06059846   Meiji Seika Pharma Initiated the Global Phase III Clinical Trials of OP0595, a Novel beta-Lactamase Inhibitor for Combatting Antimicrobial Resistance (AMR). Tokyo: Meiji Seika Pharma Ltd; 26 April 2023. https://www.meiji.com/global/news/2023/pdf/230426_01.pdf

    53 хв
  5. Communicable E9 - Avian flu: an update

    9 ВЕР.

    Communicable E9 - Avian flu: an update

    The current H5N1 avian flu outbreak in poultry and dairy cows in the US has raised the alarm on bird flu and its transmission risk across species. At present, the virus has infected 100 million birds across 48 states and 196 dairy herds across 14 states. Luckily, the H5N1 avian flu, which is very lethal in birds, does not transmit easily into humans nor does it generally cause severe and systemic symptoms when humans are infected. Still, workers most exposed to these infected animals are testing positive with 14 human cases reported so far since 2022.  In this Communicable episode, hosts Angela and Nav are joined by avian flu expert Ron Fouchier (Erasmus MC Rotterdam, Netherlands) to discuss the most recent developments of the outbreak in the US and the potential risks H5N1 virus poses to humans. Understanding of the virus from its first reported outbreak in Hong Kong in 1997 to its global prevalence today is reviewed. While H5N1 bird flu does not pose as a global human health concern at present, unchecked practices in the dairy, meat, and agricultural industry sectors, in which workers are exposed to the virus, threaten to change the status quo. Learn why the threat is even more paramount in fall when human influenza or seasonal flu is widespread, and to what extent the government should also be involved in prevention and containment measures before it becomes, in Ron’s words, another “missed opportunity.”           This episode was edited by Kathryn Hostettler and peer-reviewed by Dr. Simon Galmiche of the Institut Pasteur, Université Paris Cité, Paris, France. Literature US Centers for Disease Control and Prevention (CDC). H5 Bird Flu: Current Situation. 2024. https://www.cdc.gov/bird-flu/situation-summary

    50 хв
  6. Communicable E8 - The Nightmare Series, part 1: How to deal with Candida auris

    26 СЕРП.

    Communicable E8 - The Nightmare Series, part 1: How to deal with Candida auris

    Only known to us since 2008, Candida auris is an emerging fungal pathogen spreading quickly around the world; alarmingly, it is most commonly found in healthcare settings. C. auris sets itself apart from other Candida species with its unique tolerance to high saline and temperature environments and propensity to develop antifungal resistances that promote its survival in hospitals and healthcare facilities.  Hosts Emily McDonald and Navaneeth Narayanan are joined by fungal experts Dr. Jeffrey Rybak (St. Jude, Memphis TN) and Dr. Graham Snyder (UPMC, Pittsburgh PA) on their quest to better understand C. auris infections, the clinical challenges and knowledge gaps in C. auris research and discuss measures for prevention and containment on the levels of both the patient and the institution.  The recent emergence of C. auris as a multidrug-resistant nosocomial pathogen and its global prevalence has raised more questions than answers. Why now? Why healthcare facilities? Does climate change play a role? Are humans to blame? Tune in to find out what the experts have to say on these questions, and stay to learn about the current therapies available, what is in the antifungal pipeline and how to approach treatment from a stewardship standpoint. This episode was produced by Angela Huttner, edited by Kathryn Hostettler and peer-reviewed by Dr. Claudio Neidhöfer of University Hospital Bonn, Germany. Literature Satoh K, Makimura K, Hasumi Y, et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009 Jan;53(1):41-4. doi: 10.1111/j.1348-0421.2008.00083.x Lee WG, Shin JH, Uh Y, et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011 Sep;49(9):3139-42. doi: 10.1128/JCM.00319-11 Pfaller MA, Diekema DJ, Turnidge JD, et al. Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016. OFID. 2019 March;6(S1): S79–S94. doi: 10.1093/ofid/ofy358 Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clin Infect Dis. 2017 Jan 15;64(2):134-140. doi: 10.1093/cid/ciw691. Clancy CJ, Nguyen MH. Emergence of Candida auris: An International Call to Arms. Clin Infect Dis. 2017 Jan 15;64(2):141-143. doi: 10.1093/cid/ciw696 Rybak JM, Cuomo CA, Rogers PD. The molecular and genetic basis of antifungal resistance in the emerging fungal pathogen Candida auris. Curr Opin Microbiol. 2022 Dec;70:102208. doi: 10.1016/j.mib.2022.102208

    59 хв
  7. Communicable E7 - Melioidosis goes global

    12 СЕРП.

    Communicable E7 - Melioidosis goes global

    Once considered endemic only to tropical and subtropical climates such as Southeast Asia and northern Australia, melioidosis is expanding to non-endemic areas such as the southern US. Climate change is impacting infectious diseases, melioidosis being no exception. Now is the time to inform and prepare: as this Communicable episode’s title indicates, melioidosis is going global. Join hosts Angela Huttner and Josh Davis on their in-depth exploration of melioidosis with invited experts Dr. Ella Meumann and Prof. Bart Currie from Royal Darwin Hospital, Darwin, Australia. Topics range from melioidosis discovery, clinical presentation, diagnostic approaches and host risk factors to the disease’s expanding endemicity. Melioidosis is an infectious disease caused by the sapronotic agent Burkholderia pseudomallei and contracted by both people and animals through direct contact with contaminated soil, air or waters. Current burden estimates of 169’000 cases and 89’000 deaths per year are thought to be grossly underreported due to limited access to laboratory diagnostics and lack of clinical awareness. Experts call for melioidosis to be recognized as a neglected tropical disease in order to give this disease the urgent attention and resources it deserves. This episode was edited by Kathryn Hostettler and peer-reviewed by Dr. Goulia Ohan of Yerevan State Medical University, Armenia. Literature  Meumann EM and Currie BJ. Approach to melioidosis. CMI Comms 2024;1(1). doi: 10.1016/j.cmicom.2024.100008  Savelkoel J, Dance D. Alfred Whitmore and the Discovery of Melioidosis. Emerg Infect Dis. 2024;30(4):752-756. doi:10.3201/eid3004.230693  Limmathurotsakul D, Wongsuvan G, Aanensen D et al. Melioidosis Caused by Burkholderia pseudomallei in Drinking Water, Thailand, 2012. Emerg Infect Dis. 2014;20(2):265-268. doi: 10.3201/eid2002.121891  Petras JK, Elrod MG, Ty MC, et al. Locally acquired melioidosis linked to environment—Mississippi, 2020-2023. N Engl J Med. 2023;389:2355-2362. doi: 10.1056/NEJMoa2306448 Howes M and Currie BJ. Melioidosis and Activation from Latency: The “Time Bomb” Has Not Occurred. ASTMH. 28 May 2024;111(1): 156-160. doi 10.4269/ajtmh.24-0007

    52 хв
  8. Communicable E6 - “Sneaky viruses”: an update on hepatitis B & C before World Hepatitis Day

    25 ЛИП.

    Communicable E6 - “Sneaky viruses”: an update on hepatitis B & C before World Hepatitis Day

    Responsible for 1.3 million deaths and 2.2 million new infections per year, viral hepatitis is the second leading cause of morbidity and mortality amongst all infectious diseases, just behind tuberculosis.    Hosts Angela Huttner and Oana Sandulescu welcome special guest and leading hepatitis expert, Professor Mojca Matičič, MD, PhD (Ljubljana, Slovenia), to refresh your knowledge on the pathogenesis of hepatitis B & C infections, review the latest direct-acting antiviral (DAA) therapies, map out some countries’ successful elimination initiatives, and understand challenges remaining for others.   In recognition of World Hepatitis Day this Sunday, 28 July, a day dedicated to raising awareness about viral hepatitis, we are releasing our latest episode a few days early. The World Hepatitis Day theme this year is: it’s time for action! The Communicable team urges our listeners to inform themselves and others, and to test, treat, and vaccinate against viral hepatitis.    This episode was peer reviewed by Dr. Liem Luong of CIC Cochin Pasteur, Hôpital Cochin-Port Royal, Assistance Publique-Hôpitaux de Paris, Paris, France. Literature World Hepatitis Day 2024: It’s time for action. Geneva: World Health Organization; 2024. https://www.who.int/campaigns/world-hepatitis-day/2024 “WHO sounds alarm on viral hepatitis infections claiming 3500 lives each day.”  Geneva: World Health Organization; 9 April 2024. https://www.who.int/news/item/09-04-2024-who-sounds-alarm-on-viral-hepatitis-infections-claiming-3500-lives-each-day   Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization; 2024. doi: 10.2471/B09024.  The European Association of the Study of the Liver (EASL). EASL Congress Milan, Italy 5-8 June 2024. https://www.easlcongress.eu/  ESCMID. Cutting Edge Insights into Viral Hepatitis: Recent Scientific Breakthroughs and Clinical Updates. Lund, Sweden 13-14 June 2024. https://www.escmid.org/event-detail/cutting-edge-insights-into-viral-hepatitis-recent-scientific-breakthroughs-and-clinical-updates/  European Centre for Disease Prevention and Control (ECDC). ECDC Evidence brief: Prevention of hepatitis B and C in the EU/EEA. Stockholm: ECDC; 2024. European Centre for Disease Prevention and Control. Hepatitis C. In: ECDC. Annual epidemiological report for 2022. Stockholm: ECDC; 2024. Burnet Institute and Kirby Institute. Australia’s progress towards hepatitis C elimination: annual report 2022. Melbourne: Burnet Institute; 2022. Maticic M, Pirnat Z, Leicht A, et al. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries. Harm Reduct J. 2020 Nov 19;17(1):89. doi: 10.1186/s12954-020-00439-3

    54 хв
Переглянути всі (13)

Опис

Communicable takes on hot topics in infectious diseases and clinical microbiology. Hosted by the editors of CMI Communications, the open-access journal of ESCMID, the European Society of Clinical Microbiology & Infectious Diseases.

Інформація

  • Автор
    CMI Communications
  • Роки діяльності
    2 тис.
  • Епізоди
    13
  • Категорія
    Не відверті
  • Авторське право
    © 2024 CMI Communications

Теж може цікавити

Щоб прослухати епізоди з відвертим змістом, потрібно ввійти в систему.

Стежте за оновленнями для цього шоу

Увійдіть або зареєструйтеся, щоб стежити за шоу, зберігати епізоди й отримувати найновіші оновлення.
Виберіть країну або регіон

Африка, Близький Схід та Індія

Азіатсько-Тихоокеанський регіон

Європа

Латинська Америка та Кариби

Сполучені Штати Америки та Канада